Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bioxcel Therapeutics Inc (BTAI) just unveiled an update.
BioXcel Therapeutics, Inc. has unveiled an updated corporate overview and its business strategy, with a focus on its upcoming SERENITY At-Home Phase 3 trial. This pivotal study will explore the effectiveness and safety of BXCL501, an investigational treatment for agitation in bipolar and schizophrenia patients, in a home environment based on recent FDA feedback. The trial aims to enroll around 200 patients, assessing both safety and exploratory efficacy endpoints over 12 weeks. Additionally, a smaller study will examine the correlation between patient and professional efficacy assessments. BioXcel’s forward-looking statements highlight the company’s aspirations and ongoing research, although they come with the usual caveats of uncertainty inherent in clinical development.
For an in-depth examination of BTAI stock, go to TipRanks’ Stock Analysis page.
